Oleanolic Acid Targets the Gut-Liver Axis to Alleviate Metabolic Disorders and Hepatic Steatosis

Area of Science:

• Metabolic disorders
• Gut-liver axis
• Non-alcoholic fatty liver disease (NAFLD)

Background:

• Obesity-related non-alcoholic fatty liver disease (NAFLD) is a growing health concern.
• Hepatic lipid metabolism and gut-liver axis homeostasis are critical in NAFLD pathogenesis.
• High-fat diet (HFD) models are commonly used to study NAFLD and associated metabolic disorders.

Purpose of the Study:

• To investigate the effects of oleanolic acid (OA) on hepatic lipid metabolism and gut-liver axis homeostasis.
• To explore the molecular mechanisms underlying OA's therapeutic effects in an obesity-related NAFLD model.
• To evaluate OA's potential as a treatment for metabolic disorders and NAFLD.

Main Methods:

• Utilized a nutritional animal model of obesity-related non-alcoholic fatty liver disease (NAFLD) induced by a high-fat diet (HFD).
• Administered oleanolic acid (OA) to obese rats and assessed metabolic parameters, liver health, and gut-liver axis markers.
• Analyzed gut microbiota composition and endotoxin-mediated inflammatory pathways, including toll-like receptor 4 (TLR4).

Main Results:

• Oleanolic acid (OA) ameliorated metabolic disorders, insulin resistance, and hepatic steatosis in obese rats.
• OA restored intestinal barrier function and inhibited endotoxin-induced TLR4 pathways, reducing endotoxemia and systemic inflammation.
• OA treatment reshaped gut microbiota, decreasing the Firmicutes/Bacteroidetes ratio and increasing beneficial butyrate-producing bacteria.

Conclusions:

• Oleanolic acid (OA) demonstrates significant therapeutic potential for obesity-related NAFLD.
• OA acts through anti-inflammatory, antioxidant, and prebiotic mechanisms, mediated by the gut-liver axis.
• OA's ability to restore gut-liver axis homeostasis makes it a promising candidate for NAFLD treatment.